5.03
-0.07 (-1.37%)
| Penutupan Terdahulu | 5.10 |
| Buka | 5.09 |
| Jumlah Dagangan | 450,828 |
| Purata Dagangan (3B) | 2,072,856 |
| Modal Pasaran | 1,527,062,784 |
| Harga / Pendapatan (P/E TTM) | 50.30 |
| Harga / Pendapatan (P/E Ke hadapan) | 30.77 |
| Harga / Jualan (P/S) | 5.20 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Keuntungan | 9.66% |
| Margin Operasi (TTM) | 28.74% |
| EPS Cair (TTM) | 0.100 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 31.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 429.80% |
| Nisbah Semasa (MRQ) | 3.28 |
| Aliran Tunai Operasi (OCF TTM) | 42.51 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 44.64 M |
| Pulangan Atas Aset (ROA TTM) | 9.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | MannKind Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.33 |
|
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.66% |
| % Dimiliki oleh Institusi | 55.88% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nitorum Capital, L.P. | 31 Dec 2024 | 8,747,316 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Mar 2025 | Pengumuman | MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 |
| 26 Feb 2025 | Pengumuman | MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 19 Feb 2025 | Pengumuman | MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 |
| 06 Feb 2025 | Pengumuman | MannKind to Present at Upcoming Investor Conferences |
| 06 Jan 2025 | Pengumuman | MannKind Expands Executive Leadership Team |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |